Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

“These results underscore the clinical potential of Versamune® HPV—an HPV16-targeted immunotherapy—when used in combination with PDS01ADC and an ICI in transforming the treatment paradigm for HPV-associated cancers,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “This group of cancers includes rare cancers such as anal, penile, vaginal and vulvar cancers, and it also includes growing, higher incidence cancers such as head and neck cancer. An increasing number of head and neck cancers, including a majority of oropharyngeal cancers, are now reported to be HPV16-positive. Based on these impressive peer-reviewed results demonstrating the strong potential of Versamune® HPV as an HPV16-targeted immunotherapy, we are excited to begin our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab in recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma next month. The study also demonstrates the strength of our pipeline combination therapies that may build upon the reported potential of Versamune® HPV + standard of care.”